Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
NCT00275132
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
670
Enrollment
OTHER
Sponsor class
Conditions
Lung Cancer
Interventions
DRUG:
erlotinib hydrochloride
DRUG:
Matched placebo
Sponsor
University College, London
Collaborators
[object Object]
[object Object]